Blau Farmacêutica Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Marcelo Hahn

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	83.3%
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17

CEO

Marcelo Hahn

no data

Tenure

Mr. Marcelo Rodolfo Hahn is the Founder and serves as Chief Executive Officer at Blau Farmacêutica S/A and serves as its Deputy Chairman of the Board. Mr. Hahn served as President at Blau Farmacêutica S/A.

Blau Farmacêutica Management

Management criteria checks 0/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Recent updates

Upcoming dividend of R$0.014 per share

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 14% to R$15.71

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 14%

Blau Farmacêutica S.A. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.9% to R$19.86

Consensus revenue estimates fall by 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall by 12%

Blau Farmacêutica S.A. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.4% to R$27.39

Price target decreased by 7.1% to R$29.17

Price target decreased by 7.4% to R$31.40

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Consensus revenue estimates decrease by 12%

Consensus EPS estimates fall by 19%

First quarter 2023 earnings released: EPS: R$0.29 (vs R$0.34 in 1Q 2022)

Price target decreased by 7.7% to R$33.91

Price target decreased by 8.3% to R$34.58

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of R$0.052 per share at 3.0% yield

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Insufficient new directors

Third quarter 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued

Now 22% undervalued

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to R$37.57

Now 21% undervalued after recent price drop

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Second quarter 2021 earnings released: EPS R$0.56 (vs R$0.50 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS R$0.58 (vs R$0.21 in 1Q 2020)

CEO

Tenure